Acrylamide produces a direct, dose-dependent and specific inhibition of oxidative metabolism in motoneurons.
The mechanism of action of acrylamide (ACR) in producing a central-peripheral distal axonopathy is unknown. We have tested the hypothesis that ACR inhibition of enzymes of oxidative metabolism is responsible for compromise of the energy supply, thereby producing the neuropathy. A single 50 mg/kg i.p. dose of ACR resulted in a 33.4% decrease in NADH-tetrazolium reductase (NADH-TR) (indicative of oxidative metabolism) activity in rat soleus motoneurons within one hour of injection. Methylene bis ACR (Mb-ACR), a non-neurotoxic analogue, produced a much smaller (6.7%) decrease in NADH-TR activity. Restoration of normal NADH-TR activity following that single injection occurred in 3 days. In vitro histochemical assays demonstrated a dose-dependent inhibition of motoneuron NADH-TR activity (10-54%) by 1-10mM ACR. Equimolar Mb-ACR produced significantly less inhibition. The rapid, dose-dependent and specific inhibition of this oxidative enzyme activity by ACR provides evidence in support of the energy hypothesis of ACR-induced neuropathy and more specifically suggests that oxidative enzyme inhibitions are a critical site of ACR action.